SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
SpringWorks Therapeutics, Inc. - common stock (SWTX)
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
R&D Expenses : R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. SG&A Expenses : SG&A expenses rose to $197.6 million in 2023 due to commercial readiness activities for OGSIVEO. Net Loss : Net loss widened to $325.1 million in 2023, with a loss per share of $5.15. Cash Position : Ended 2023 with a strong cash position of $662.6 million. Patent Protection : New patents issued for OGSIVEO and mirdametinib, extending protection into 2043. Warning! GuruFocus has detected 3 Warning Sign with SWTX. On February 27, 2024, SpringWorks Therapeutics Inc ( NASDAQ:SWTX ), a clinical-stage biopharmaceutical company, released its 8-K filing , detailing the financial results for the fourth quarter and full year of 2023. SpringWorks Therapeutics is dedicated to developing and commercializing medicines for rare diseases and cancer, with a focus on precision medicine. The company has recently celebrated the FDA approval and succ
Show less
Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SWTX alerts
High impacting SpringWorks Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
SWTX
News
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.MarketBeat
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceGlobeNewswire
SWTX
Earnings
- 5/2/24 - Beat
SWTX
Sec Filings
- 6/3/24 - Form 144
- 6/3/24 - Form 144
- 6/3/24 - Form 144
- SWTX's page on the SEC website